Immunoblockade of Dkk-1 has been successfully achieved in multiple myeloma [20] and OS [21], but systemic Dkk-1 levels can be substantial [10, 12], requiring large doses of antibodies. The gene discussed is DKK1; the disease is plasma cell myeloma.